WO1995004525A3 - Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection - Google Patents

Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection Download PDF

Info

Publication number
WO1995004525A3
WO1995004525A3 PCT/US1994/008741 US9408741W WO9504525A3 WO 1995004525 A3 WO1995004525 A3 WO 1995004525A3 US 9408741 W US9408741 W US 9408741W WO 9504525 A3 WO9504525 A3 WO 9504525A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
necrosis factor
tumor necrosis
hiv infection
therapeutic compositions
Prior art date
Application number
PCT/US1994/008741
Other languages
French (fr)
Other versions
WO1995004525A2 (en
Inventor
Peter J Andrulis Jr
Issac Angres
Original Assignee
Andrulis Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrulis Pharm Corp filed Critical Andrulis Pharm Corp
Priority to EP94922777A priority Critical patent/EP0712310A1/en
Priority to AU73763/94A priority patent/AU7376394A/en
Publication of WO1995004525A2 publication Critical patent/WO1995004525A2/en
Publication of WO1995004525A3 publication Critical patent/WO1995004525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprising: (a) a tumor necrosis factor inhibitor; (b) a compound selected from the group consisting of reverse transcriptase inhibitor, protease inhibitor, a gene inhibitor, myristoylation inhibitor, cell-virus binding inhibitor, LTR promoter site inhibitor, ribosome inactivators, platelet aggregation inhibitor and prophylactic and therapeutic HIV vaccine, and (c) a pharmaceutical inert nontoxic carrier are described.
PCT/US1994/008741 1993-08-04 1994-08-03 Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection WO1995004525A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94922777A EP0712310A1 (en) 1993-08-04 1994-08-03 Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
AU73763/94A AU7376394A (en) 1993-08-04 1994-08-03 Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10175293A 1993-08-04 1993-08-04
US08/101,752 1993-08-04

Publications (2)

Publication Number Publication Date
WO1995004525A2 WO1995004525A2 (en) 1995-02-16
WO1995004525A3 true WO1995004525A3 (en) 1995-06-01

Family

ID=22286225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008741 WO1995004525A2 (en) 1993-08-04 1994-08-03 Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection

Country Status (3)

Country Link
EP (1) EP0712310A1 (en)
AU (1) AU7376394A (en)
WO (1) WO1995004525A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032587A1 (en) * 1996-03-04 1997-09-12 Dana-Farber Cancer Institute Methods for treating viral infections
FR2756737B1 (en) * 1996-12-05 1999-01-08 Rhone Poulenc Rorer Sa APPLICATION OF THALIDOMIDE TO THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009203A1 (en) * 1990-11-21 1992-06-11 Smithkline Beecham Corporation Tnf inhibitors
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009203A1 (en) * 1990-11-21 1992-06-11 Smithkline Beecham Corporation Tnf inhibitors
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D.R.LUKE ET AL.: "Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients", INT.J.CLIN.PHARMACOL.THER.TOXICOL., vol. 31, no. 7, 1993, pages 343 - 350 *
FATEMEH FAZELY ET AL.: "Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells", BLOOD, vol. 77, no. 8, 1991, pages 1653 - 1656 *
GUILLERMO J. RUIZ-ARGÜELLES ET AL.: "La pentoxifyllina en el tratamiento de SIDA", REV.INV.CLIN., vol. 44, no. 2, 1992, pages 285 - 286 *
M.ODEH: "The role of tumor necrosis factor-alpha in acquired immunodeficiency syndrome", J.INTERN.MED., vol. 228, no. 6, 1990, pages 549 - 556 *
ZHANG LIN ET AL.: "Pentoxifylline (Trental) enhances the antiretroviral activity of didanosine (dideoxyinosine, ddI)", INT. CONF. AIDS, vol. 8, no. 2, 1992, pages A57 *

Also Published As

Publication number Publication date
WO1995004525A2 (en) 1995-02-16
AU7376394A (en) 1995-02-28
EP0712310A1 (en) 1996-05-22

Similar Documents

Publication Publication Date Title
HK1115544A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
AU7669794A (en) Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
CA2215066A1 (en) Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
WO2001035941A8 (en) Novel composition based on a thiazolidinedione and metformin and use
AU4443893A (en) Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
CA2037101A1 (en) Omeprazole Compositions Designed for Administration in Rectum
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
CA2277877A1 (en) Nitric oxide synthase inhibitors
CA2065109A1 (en) Refrigerant compositions
EP0893437A4 (en) Tryptase inhibitor and novel guanidino derivatives
AU5845486A (en) Selected difluoro derivatives
AU2436792A (en) Quinazoline derivatives as inhibitors of hiv reverse transcriptase
CA2163706A1 (en) Amino Acid Derivatives of Paclitaxel
HUP0004531A3 (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
EP0957093A3 (en) Retrovial protease inhibitors
WO2002076499A3 (en) Combination treatment of pancreatic cancer
AU3627289A (en) Pharmaceutical products
AU633733B2 (en) Percutaneous preparation containing estradiol
CA2141056A1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
WO1995004525A3 (en) Use of tumor necrosis factor inhibitors together with antiviral agents and therapeutic compositions thereof against hiv infection
DK315889D0 (en) ANTIVIRAL COMBINATIONS, RELATIONSHIPS USED HEREIN, AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMBINATIONS.
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
CA2114859A1 (en) Cytotoxic and antiviral compound
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994922777

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994922777

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994922777

Country of ref document: EP